<p>Pacira BioSciences（纳斯达克股票代码：PCRX - 获取免费报告）在周一向投资者发布的研究报告中被巴克莱的股票分析师上调至 “持有” 评级，Zacks.com 报道。</p>
<p>获取 <strong>Pacira BioSciences</strong> 的提醒：</p>
<p>PCRX 已成为其他多份报告的主题。华尔街禅在 11 月 8 日的研究报告中将 Pacira BioSciences 的股票评级从 “买入” 上调至 “强力买入”。HC Wainwright 在 11 月 17 日的报告中重申了 “买入” 评级，并对 Pacira BioSciences 的股票设定了 38.00 美元的目标价。Truist Financial 在 11 月 7 日的研究报告中将 Pacira BioSciences 的股票目标价从 30.00 美元下调至 28.00 美元，并对该公司设定了 “买入” 评级。Weiss Ratings 在周一的报告中重申了 Pacira BioSciences 的 “卖出（d+）” 评级。最后，Zacks Research 在 8 月 14 日的研究报告中将 Pacira BioSciences 的评级从 “强烈卖出” 上调至 “持有”。三位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 28.20 美元。</p>
<p><strong>查看我们最新的 Pacira BioSciences 股票报告</strong></p>
<h2>Pacira BioSciences 股票表现</h2>
<p>纳斯达克股票代码：PCRX 的股票在周一开盘价为 24.77 美元。该公司的流动比率为 5.26，速动比率为 3.78，债务与股本比率为 0.52。Pacira BioSciences 的 1 年最低价为 18.17 美元，1 年最高价为 27.64 美元。该股票的市值为 10.7 亿美元，市盈率为 55.05，贝塔值为 0.23。该公司的 50 日移动平均价格为 23.09 美元，200 日移动平均价格为 24.13 美元。</p>
<p>Pacira BioSciences（纳斯达克股票代码：PCRX - 获取免费报告）最近在 11 月 6 日发布了其财报。该公司报告本季度每股收益（EPS）为 0.70 美元，超出市场共识预期的 0.65 美元，超出幅度为 0.05 美元。Pacira BioSciences 的净利润率为 2.99%，股本回报率为 12.82%。该公司本季度的收入为 1.7952 亿美元，而分析师预期为 1.8286 亿美元。去年同期，该公司每股收益为 0.79 美元。该公司的季度收入同比增长 6.5%。股票分析师预测 Pacira BioSciences 在本年度将发布 2.41 美元的每股收益。</p>
<h2>Pacira BioSciences 的内部交易</h2>
<p>在其他 Pacira BioSciences 的新闻中，内部人士 Jonathan Slonin 在 11 月 17 日的交易中出售了 3,960 股 Pacira BioSciences 的股票。该股票以平均价格 24.09 美元出售，总价值为 95,396.40 美元。出售后，该内部人士持有该公司 178,367 股股票，价值为 4,296,861.03 美元。此交易代表其持股比例下降了 2.17%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。公司内部人士持有该公司 6.40% 的股票。</p>
<h2>机构投资者对 Pacira BioSciences 的看法</h2>
<p>机构投资者最近买入和卖出了该公司的股票。Alyeska Investment Group L.P.在第一季度购买了 Pacira BioSciences 的新头寸，金额约为 32,506,000 美元。Doma Perpetual Capital Management LLC 在第三季度将其在 Pacira BioSciences 的持仓提高了 49.7%。Doma Perpetual Capital Management LLC 现在拥有该公司 2,701,324 股股票，价值 69,613,000 美元，此前在上个季度又购买了 897,255 股。Balyasny Asset Management L.P.在第二季度将其在 Pacira BioSciences 的持仓提高了 36.1%。Balyasny Asset Management L.P.现在拥有该公司 2,130,733 股股票，价值 50,925,000 美元，此前在上个季度又购买了 565,288 股。American Century Companies Inc.在第一季度将其在 Pacira BioSciences 的持仓提高了 392.2%。American Century Companies Inc.现在拥有该公司 667,423 股股票，价值 16,585,000 美元，此前在上个季度又购买了 531,831 股。最后，Nuveen LLC 在第一季度购买了 Pacira BioSciences 的新头寸，价值为 12,884,000 美元。机构投资者持有该公司 99.73% 的股票。</p>
<h2>Pacira BioSciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Pacira Biosciences, Inc 是一家控股公司，专注于提供非阿片类疼痛管理和再生健康解决方案，以改善患者在神经疼痛路径上的体验。其产品包括 EXPAREL、iovera 和 DepoFoam。该公司成立于 2006 年 12 月，总部位于佛罗里达州坦帕。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Pacira BioSciences</li>
<li>如何交易便士股票：逐步指南</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>3 只家居改善股票可以升级你的投资组合</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年爆发</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>安海斯 - 布希收购 BeatBox 以赢得年轻饮酒者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Pacira BioSciences 吗？</h2>
<p>在考虑 Pacira BioSciences 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Pacira BioSciences 并不在名单上。</p>
<p>虽然 Pacira BioSciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Pacira制药

<p>巴克莱将 Pacira BioSciences（NASDAQ:PCRX）的评级上调至 “持有”。其他分析师的评级各不相同：华尔街禅将其评级上调至 “强力买入”，HC Wainwright 维持 “买入” 评级，目标价为 38 美元，Truist Financial 将目标价下调至 28 美元但保持 “买入” 评级，Weiss Ratings 重申 “卖出” 评级，Zacks Research 则上调至 “持有”。该股票以 24.77 美元开盘，市值为 10.7 亿美元</p>

<p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) was upgraded by stock analysts at Barclays to a &#34;hold&#34; rating in a research note issued to investors on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Pacira BioSciences（纳斯达克股票代码：PCRX - 获取免费报告）在周一向投资者发布的研究报告中被巴克莱的股票分析师上调至 “持有” 评级，Zacks.com 报道。</p>
</div><p>Get <strong>Pacira BioSciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Pacira BioSciences</strong> 的提醒：</p>
</div><p>PCRX has been the topic of a number of other reports. Wall Street Zen upgraded shares of Pacira BioSciences from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, November 8th. HC Wainwright reissued a &#34;buy&#34; rating and issued a $38.00 price target on shares of Pacira BioSciences in a report on Monday, November 17th. Truist Financial lowered their price objective on shares of Pacira BioSciences from $30.00 to $28.00 and set a &#34;buy&#34; rating for the company in a research report on Friday, November 7th. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Pacira BioSciences in a report on Monday. Finally, Zacks Research raised Pacira BioSciences from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, August 14th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average target price of $28.20.</p>
<div class="lb-trans"><p>PCRX 已成为其他多份报告的主题。华尔街禅在 11 月 8 日的研究报告中将 Pacira BioSciences 的股票评级从 “买入” 上调至 “强力买入”。HC Wainwright 在 11 月 17 日的报告中重申了 “买入” 评级，并对 Pacira BioSciences 的股票设定了 38.00 美元的目标价。Truist Financial 在 11 月 7 日的研究报告中将 Pacira BioSciences 的股票目标价从 30.00 美元下调至 28.00 美元，并对该公司设定了 “买入” 评级。Weiss Ratings 在周一的报告中重申了 Pacira BioSciences 的 “卖出（d+）” 评级。最后，Zacks Research 在 8 月 14 日的研究报告中将 Pacira BioSciences 的评级从 “强烈卖出” 上调至 “持有”。三位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 28.20 美元。</p>
</div><p><strong>View Our Latest Stock Report on Pacira BioSciences</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Pacira BioSciences 股票报告</strong></p>
</div><h2>Pacira BioSciences Stock Performance</h2>
<div class="lb-trans"><h2>Pacira BioSciences 股票表现</h2>
</div><p>Shares of NASDAQ:PCRX opened at $24.77 on Monday. The company has a current ratio of 5.26, a quick ratio of 3.78 and a debt-to-equity ratio of 0.52. Pacira BioSciences has a 1-year low of $18.17 and a 1-year high of $27.64. The stock has a market capitalization of $1.07 billion, a P/E ratio of 55.05 and a beta of 0.23. The business has a 50-day moving average price of $23.09 and a two-hundred day moving average price of $24.13.</p>
<div class="lb-trans"><p>纳斯达克股票代码：PCRX 的股票在周一开盘价为 24.77 美元。该公司的流动比率为 5.26，速动比率为 3.78，债务与股本比率为 0.52。Pacira BioSciences 的 1 年最低价为 18.17 美元，1 年最高价为 27.64 美元。该股票的市值为 10.7 亿美元，市盈率为 55.05，贝塔值为 0.23。该公司的 50 日移动平均价格为 23.09 美元，200 日移动平均价格为 24.13 美元。</p>
</div><p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Pacira BioSciences had a net margin of 2.99% and a return on equity of 12.82%. The company had revenue of $179.52 million for the quarter, compared to analyst estimates of $182.86 million. During the same quarter last year, the firm earned $0.79 EPS. The company's revenue for the quarter was up 6.5% on a year-over-year basis. Equities analysts predict that Pacira BioSciences will post 2.41 earnings per share for the current year.</p>
<div class="lb-trans"><p>Pacira BioSciences（纳斯达克股票代码：PCRX - 获取免费报告）最近在 11 月 6 日发布了其财报。该公司报告本季度每股收益（EPS）为 0.70 美元，超出市场共识预期的 0.65 美元，超出幅度为 0.05 美元。Pacira BioSciences 的净利润率为 2.99%，股本回报率为 12.82%。该公司本季度的收入为 1.7952 亿美元，而分析师预期为 1.8286 亿美元。去年同期，该公司每股收益为 0.79 美元。该公司的季度收入同比增长 6.5%。股票分析师预测 Pacira BioSciences 在本年度将发布 2.41 美元的每股收益。</p>
</div><h2>Insider Transactions at Pacira BioSciences</h2>
<div class="lb-trans"><h2>Pacira BioSciences 的内部交易</h2>
</div><p>In other Pacira BioSciences news, insider Jonathan Slonin sold 3,960 shares of Pacira BioSciences stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $24.09, for a total value of $95,396.40. Following the sale, the insider owned 178,367 shares of the company's stock, valued at $4,296,861.03. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 6.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Pacira BioSciences 的新闻中，内部人士 Jonathan Slonin 在 11 月 17 日的交易中出售了 3,960 股 Pacira BioSciences 的股票。该股票以平均价格 24.09 美元出售，总价值为 95,396.40 美元。出售后，该内部人士持有该公司 178,367 股股票，价值为 4,296,861.03 美元。此交易代表其持股比例下降了 2.17%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。公司内部人士持有该公司 6.40% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Pacira BioSciences</h2>
<div class="lb-trans"><h2>机构投资者对 Pacira BioSciences 的看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new position in shares of Pacira BioSciences during the 1st quarter worth approximately $32,506,000. Doma Perpetual Capital Management LLC lifted its position in shares of Pacira BioSciences by 49.7% in the third quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company's stock worth $69,613,000 after purchasing an additional 897,255 shares in the last quarter. Balyasny Asset Management L.P. boosted its holdings in Pacira BioSciences by 36.1% during the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company's stock worth $50,925,000 after purchasing an additional 565,288 shares during the last quarter. American Century Companies Inc. grew its position in Pacira BioSciences by 392.2% in the first quarter. American Century Companies Inc. now owns 667,423 shares of the company's stock valued at $16,585,000 after purchasing an additional 531,831 shares in the last quarter. Finally, Nuveen LLC bought a new position in Pacira BioSciences in the first quarter valued at $12,884,000. Institutional investors own 99.73% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该公司的股票。Alyeska Investment Group L.P.在第一季度购买了 Pacira BioSciences 的新头寸，金额约为 32,506,000 美元。Doma Perpetual Capital Management LLC 在第三季度将其在 Pacira BioSciences 的持仓提高了 49.7%。Doma Perpetual Capital Management LLC 现在拥有该公司 2,701,324 股股票，价值 69,613,000 美元，此前在上个季度又购买了 897,255 股。Balyasny Asset Management L.P.在第二季度将其在 Pacira BioSciences 的持仓提高了 36.1%。Balyasny Asset Management L.P.现在拥有该公司 2,130,733 股股票，价值 50,925,000 美元，此前在上个季度又购买了 565,288 股。American Century Companies Inc.在第一季度将其在 Pacira BioSciences 的持仓提高了 392.2%。American Century Companies Inc.现在拥有该公司 667,423 股股票，价值 16,585,000 美元，此前在上个季度又购买了 531,831 股。最后，Nuveen LLC 在第一季度购买了 Pacira BioSciences 的新头寸，价值为 12,884,000 美元。机构投资者持有该公司 99.73% 的股票。</p>
</div><h2>Pacira BioSciences Company Profile</h2>
<div class="lb-trans"><h2>Pacira BioSciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.</p>
<div class="lb-trans"><p>Pacira Biosciences, Inc 是一家控股公司，专注于提供非阿片类疼痛管理和再生健康解决方案，以改善患者在神经疼痛路径上的体验。其产品包括 EXPAREL、iovera 和 DepoFoam。该公司成立于 2006 年 12 月，总部位于佛罗里达州坦帕。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Pacira BioSciences</li>
<li>How to trade penny stocks: A step-by-step guide</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Pacira BioSciences</li>
<li>如何交易便士股票：逐步指南</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>3 只家居改善股票可以升级你的投资组合</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年爆发</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>安海斯 - 布希收购 BeatBox 以赢得年轻饮酒者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pacira BioSciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Pacira BioSciences 吗？</h2>
</div><p>Before you consider Pacira BioSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Pacira BioSciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Pacira BioSciences 并不在名单上。</p>
</div><p>While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Pacira BioSciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pacira BioSciences（纳斯达克代码：PCRX）在巴克莱的评级被上调至持有